Novavax Inc (NVAX.OQ)
1.64USD
25 Apr 2018
$0.06 (+3.80%)
$1.58
$1.59
$1.67
$1.53
1,628,769
1,907,073
$2.75
$0.73
About
Overall
| Beta: | 1.98 |
| Market Cap(Mil.): | $338.31 |
| Shares Outstanding(Mil.): | 294.18 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| NVAX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 84.02 | 32.74 |
| EPS (TTM): | -0.77 | -- | -- |
| ROI: | -57.83 | 1.58 | 14.38 |
| ROE: | -829.23 | 2.41 | 16.07 |
BRIEF-Novavax Prices Public Offering 30.3 Mln Common Shares At $1.65 Per Share
* SAYS PUBLIC OFFERING OF 30.3 MILLION COMMON SHARES PRICED AT $1.65PER SHARE
BRIEF-Novavax Inc Q4 Loss Per Share $0.16
* NOVAVAX PROVIDES CORPORATE UPDATE AND REPORT OF FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS
BRIEF-Novavax Inc Promotes John Trizzino To CFO Role
* NOVAVAX PROMOTES JOHN J. TRIZZINO TO EXPANDED ROLE AS CHIEF BUSINESS OFFICER AND CHIEF FINANCIAL OFFICER
BRIEF-Novavax Sees Phase 2 Trial Of Nanoflu Vaccine To Begin In Q3 2018
* SAYS PHASE 2 TRIAL OF NANOFLU VACCINE EXPECTED TO BEGIN IN Q3 OF 2018
BRIEF-Novavax Inc Files For Mixed Shelf Of Up To $200 Mln
* NOVAVAX INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2zNiPwp) Further company coverage:
BRIEF-Novavax Files Prospectus Supplement Related To Issuance, Sale Of Up To $75 Mln Of Common Stock
* NOVAVAX INC FILES PROSPECTUS SUPPLEMENT RELATES TO THE ISSUANCE AND SALE OF UP TO $75 MILLION OF COMMON STOCK -SEC FILING Source text: (http://bit.ly/2Edci1c) Further company coverage:
BRIEF-Novavax Continues Phase 3 Trial Of RSV F Vaccine For Infants Via Maternal Immunization
* NOVAVAX CONTINUES PHASE 3 TRIAL OF THE RSV F VACCINE FOR INFANTS VIA MATERNAL IMMUNIZATION AND PROVIDES UPDATE ON PHASE 1/2 TRIAL OF THE NANOFLU™ VACCINE Source text for Eikon: Further company coverage:
BRIEF-Novavax Q3 loss per share $0.15
* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S
BRIEF-Novavax reports Q3 loss per share $0.15
* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S
Competitors
| Price | Chg | |
|---|---|---|
| Novartis AG (NOVN.S) | CHF75.24 | -0.52 |
| Merck & Co., Inc. (MRK.N) | $59.63 | -0.46 |
| Sanofi SA (SASY.PA) | €65.87 | -- |
| GlaxoSmithKline plc (GSK.L) | 1,412.20 | -50.00 |
| AstraZeneca plc (AZN.L) | 4,991.00 | +1.50 |
Estimates